The FDA, after a priority rapid review, approved a new drug for the treatment of advanced breast cancer. This drug will benefit women whose cancer has spread (metastasized) as well as women with localized breast tumors that have become resistant to standard treatments.
The study showed that the new drug, Ixempra, stopped tumor growth when combined with another standard anti-cancer drug treatment, Xeloda. Even when given alone, however, Ixempra shrunk breast tumors in 12% of the patients.
